Neerja Kushwaha1, Sudeep Kumar2, Mohd Anas Sheikh3, Joseph Philip4, Sanjeevan Sharma5, Amit Kumar Biswas6, Rajneesh Kumar Joshi7. 1. Classified Specialist (Immunohematology & Blood Transfusion), Command Hospital (Central Command), Lucknow, India. 2. Classified Specialist (Immunohematology & Blood Transfusion), AFTC, Delhi Cantt, India. 3. Resident, Dept of Immunohematology & Blood Transfusion, Armed Forces Medical College, Pune 40, India. 4. Professor & Head (Immunohematology & Transfusion Medicine), Bharati Vidyapeeth Medical College & Hospital, Pune 40, India. 5. Senior Advisor (Medicine & Clinical Hematology), Command Hospital (Central Command), Lucknow, India. 6. Associate Professor, Dept of Immunohematology & Blood Transfusion, Armed Forces Medical College, Pune 40, India. 7. ADH, HQ 15 Corps, C/o 56 APO.
Abstract
Background: Treatment with high-dose chemotherapy and stem cell transplantation has prolonged survival in patients of multiple myeloma (MM). A dose-response relationship between number of CD34+ cells infused and leukocyte and platelet recovery, exists. Patients receiving dose of <2.0 × 106 CD34+ cells/kg have delayed engraftment. The level of optimal cutoff for accelerated engraftment is yet to be validated. Hence, this study was undertaken to study the association of CD 34+ cell dose with engraftment kinetics in patients of MM who underwent autolgous peripheral blood stem cell transplant (PBSCT). Methods: We retrospectively analyzed 19 patients of MM who underwent PBSCT at our center between December 2016 to December 2018. Complete blood counts were carried out daily after transplantation to record neutrophil and platelet engraftment. Results: Based on the CD34+ cell dose given : <5 × 106/kg (category 1), 5-10 × 106/kg (category 2), >5 × 106/kg (category 3), the mean (SD) neutrophil engraftment time was 11.3 (0.5) days, 10.6 (0.9) days, and 10.2 (1.3) days respectively. Platelet engraftment time was 12.4 (2.60) days, 10.6 (1.14) days, and 11.2 (1.64) days for category 1, 2, and 3 patients, respectively. Correlation co-efficient between CD 34+cell dose and days for neutrophil and platelet engraftment was found to be -0.24 and -0.20, respectively. Time for neutrophil engraftment was found to be significantly associated with CD34+ cell dose category. Conclusion: CD 34+ cell dose appears as the strongest predictor of leukocyte and platelet engraftment. CD 34+ cell dose of >5.0 × 106 cells/kg leads to an accelerated neutrophil and platelet engraftment in patients of MM.
Background: Treatment with high-dose chemotherapy and stem cell transplantation has prolonged survival in patients of multiple myeloma (MM). A dose-response relationship between number of CD34+ cells infused and leukocyte and platelet recovery, exists. Patients receiving dose of <2.0 × 106 CD34+ cells/kg have delayed engraftment. The level of optimal cutoff for accelerated engraftment is yet to be validated. Hence, this study was undertaken to study the association of CD 34+ cell dose with engraftment kinetics in patients of MM who underwent autolgous peripheral blood stem cell transplant (PBSCT). Methods: We retrospectively analyzed 19 patients of MM who underwent PBSCT at our center between December 2016 to December 2018. Complete blood counts were carried out daily after transplantation to record neutrophil and platelet engraftment. Results: Based on the CD34+ cell dose given : <5 × 106/kg (category 1), 5-10 × 106/kg (category 2), >5 × 106/kg (category 3), the mean (SD) neutrophil engraftment time was 11.3 (0.5) days, 10.6 (0.9) days, and 10.2 (1.3) days respectively. Platelet engraftment time was 12.4 (2.60) days, 10.6 (1.14) days, and 11.2 (1.64) days for category 1, 2, and 3 patients, respectively. Correlation co-efficient between CD 34+cell dose and days for neutrophil and platelet engraftment was found to be -0.24 and -0.20, respectively. Time for neutrophil engraftment was found to be significantly associated with CD34+ cell dose category. Conclusion: CD 34+ cell dose appears as the strongest predictor of leukocyte and platelet engraftment. CD 34+ cell dose of >5.0 × 106 cells/kg leads to an accelerated neutrophil and platelet engraftment in patients of MM.
Authors: K Remes; I Matinlauri; S Grenman; M Itälä; M Kauppila; T T Pelliniemi; E Salminen; R Vanharanta; A Rajamäki Journal: J Hematother Date: 1997-02
Authors: Doris Posch; Werner Rabitsch; Philipp Wohlfarth; Michael Leiner; Edit Porpaczy; Johannes Drach; Markus Raderer; Wolfgang Lamm Journal: Oncology Date: 2017-08-12 Impact factor: 2.935
Authors: J E Kiss; W B Rybka; A Winkelstein; M deMagalhaes-Silverman; J Lister; P D'Andrea; E D Ball Journal: Bone Marrow Transplant Date: 1997-02 Impact factor: 5.483
Authors: G Tricot; S Jagannath; D Vesole; J Nelson; S Tindle; L Miller; B Cheson; J Crowley; B Barlogie Journal: Blood Date: 1995-01-15 Impact factor: 22.113
Authors: Mohd Nazri Hassan; Hafizuddin Mohamed Fauzi; Azlan Husin; Rapiaah Mustaffa; Rosline Hassan; Mohd Ismail Ibrahim; Noor Haslina Mohd Noor Journal: Oman Med J Date: 2019-01